GlassScriptPhysician profile
Devin T Miller
NPI 1942567482
$2,483.81
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.47 · 2020: $247 · 2021: $258 · 2022: $293 · 2023: $881 · 2024: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $856 · Consulting Fee: $525 · Food and Beverage: $143 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $856.25 |
| Consulting Fee | $525.00 |
| Food and Beverage | $143.28 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $936.88 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $780.55 | 2021-2024 | Lynparza |
| Intuitive Surgical, INC. | $148.92 | 2022 | |
| Abbvie INC. | $124.75 | 2022 | |
| Ethicon US, LLC | $70.02 | 2020-2021 | |
| Pfizer INC. | $69.99 | 2024 | |
| Tesaro, INC. | $61.03 | 2019 | |
| Genzyme Corporation | $53.51 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $42.28 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $24.82 | 2023 | Imbruvica |
| Clovis Oncology, INC. | $24.10 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $20.06 | 2020 | |
| Puma Biotechnology, INC. | $19.34 | 2019 | |
| Incyte Corporation | $19.06 | 2020 | |
| Eusa Pharma (US) LLC | $16.83 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $16.54 | 2020 | |
| Lilly USA, LLC | $16.22 | 2020 | |
| Emd Serono, INC. | $13.64 | 2020 | |
| Merck Sharp & Dohme LLC | $13.28 | 2020 | |
| Aurobindo Pharma USA, INC. | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.